Using an Internet Study to Improve Adherence for Psoriasis Patients

An investigator-blinded, prospective study of subjects with mild to moderate psoriasis will
be conducted. Forty subjects ages 18 years and older will be enrolled.The Internet-based
survey will be piloted to evaluate its effect on adherence to topical psoriasis medication.
Subjects randomized in a 1:1 ratio to the Internet-survey group will log their impression of
the state of their psoriasis on a weekly basis. Subjects in both the intervention and control
groups will receive standard-of-care topical fluocinonide 0.05% ointment to be applied to
affected areas on the skin twice daily. Adherence to fluocinonide will be assessed using
Medication Event Monitoring System (MEMS®) caps, electronic monitors affixed to the
medication containers. Investigators and subjects will be blinded to the adherence data until
the final (Month 12) treatment visit.

Inclusion Criteria:

- Any male or female 18 years or older of age with a diagnosis of mild to moderate
psoriasis by a dermatologist will be eligible for participation.

- Less than 20% of body surface involvement for psoriasis.

- Subject is capable of understanding and willing to provide a signed and dated written
voluntary informed consent before any protocol specific procedures are performed.

- The subject is able to complete the study and comply with study instructions,
including attending all study visits.

- In general good health with no other skin disease, disease state or physical condition
which would impair evaluation of psoriasis or which would increase health risk by
study participation

Exclusion Criteria:

- Individuals younger than 18 years of age.

- Known allergy or sensitivity to topical fluocinonide.

- Inability to complete all study-related visits, or inability to complete the Internet
survey due to inadequate Internet access.

- Introduction of any other prescription medication, topical or systemic, for psoriasis
while participating in the study. Subjects who are on systemic anti-inflammatory
treatments for psoriasis must be on a stable dose for at least 3 months prior to
enrollment.

- Any skin condition or disease that may require concurrent therapy or may confound
evaluations

- Current enrollment in any research study involving an investigational drug